The Angiogenesis Foundation convened an expert roundtable on using effective health policy to optimize long-term AMD outcomes with anti-VEGF treatment. The Foundation invited healthcare policy influencers, administrators, and retina experts to share their perspectives on current and imminent issues surrounding policy and regulatory change, their implications on anti-VEGF treatment for wet AMD, and their recommendations for strategies to optimize long-term treatment outcomes.

Click here for Improving Long-Term Patient Outcomes for Exudative Age-Related Macular Degeneration CME Course

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with age-related macular degeneration.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

1. Interpret regulatory guidance and its application to individual patient needs
2. Understand payer mandates, reimbursement policy changes, and potential consequences on patient outcomes
3. Describe the potential impact of the Medicare's new Quality Payment Program and the Medicare Merit-based Incentive Program for Physicians on reimbursement and patient outcomes
4. Make recommendations on how to use effective health policy to optimize long-term patient outcomes for wet AMD

FACULTY

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Non-faculty: Jeffrey McRae; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and the Angiogenesis Foundation.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and the Angiogenesis Foundation. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, the Angiogenesis Foundation, and Regeneron Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.